Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
2003 1
2006 1
2007 1
2009 1
2010 3
2011 1
2013 3
2015 2
2017 4
2018 1
2019 1
2020 1
2021 2
2022 1
2023 2
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
Chemoradiation of rectal cancer.
Arrazubi V, Suárez J, Novas P, Pérez-Hoyos MT, Vera R, Martínez Del Prado P. Arrazubi V, et al. Among authors: martinez del prado p. Minerva Chir. 2013 Feb;68(1):11-26. Minerva Chir. 2013. PMID: 23584263 Review.
Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer.
Sánchez-Magraner L, Gumuzio J, Miles J, Quimi N, Martínez Del Prado P, Abad-Villar MT, Pikabea F, Ortega L, Etxezarraga C, Martín-Algarra S, Lozano MD, Saiz-Camin M, Egurrola-Izquierdo M, Barredo-Santamaría I, Saiz-López A, Gomez-Mediavilla J, Segues-Merino N, Juaristi-Abaunz MA, Urruticoechea A, Geraedts EJ, van Elst K, Claessens NJM, Italiano A, Applebee CJ, Del Castillo S, Evans C, Aguirre F, Parker PJ, Calleja V. Sánchez-Magraner L, et al. Among authors: martinez del prado p. J Clin Oncol. 2023 May 10;41(14):2561-2570. doi: 10.1200/JCO.22.01748. Epub 2023 Feb 23. J Clin Oncol. 2023. PMID: 36821809 Free PMC article.
Functional proteomics outlines the complexity of breast cancer molecular subtypes.
Gámez-Pozo A, Trilla-Fuertes L, Berges-Soria J, Selevsek N, López-Vacas R, Díaz-Almirón M, Nanni P, Arevalillo JM, Navarro H, Grossmann J, Gayá Moreno F, Gómez Rioja R, Prado-Vázquez G, Zapater-Moros A, Main P, Feliú J, Martínez Del Prado P, Zamora P, Ciruelos E, Espinosa E, Fresno Vara JÁ. Gámez-Pozo A, et al. Among authors: martinez del prado p. Sci Rep. 2017 Aug 30;7(1):10100. doi: 10.1038/s41598-017-10493-w. Sci Rep. 2017. PMID: 28855612 Free PMC article.
Screening for epidermal growth factor receptor mutations in lung cancer.
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group. Rosell R, et al. N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19. N Engl J Med. 2009. PMID: 19692684 Free article.
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial.
Carmona-Bayonas A, Verso M, Sánchez Cánovas M, Rubio Pérez J, García de Herreros M, Martínez Del Prado P, Fernández Pérez I, Quintanar Verduguez T, Obispo Portero B, Pachón Olmos V, Gómez D, Ortega L, Serrano Moyano M, M Brozos E, Biosca M, Antonio Rebollo M, Teijeira Sanchez L, Hernández Pérez C, David Cumplido Burón J, Martínez Lago N, García Pérez E, Muñoz Langa J, Pérez Segura P, Martínez de Castro E, Jimenez-Fonseca P, Agnelli G, Muñoz A. Carmona-Bayonas A, et al. Among authors: martinez del prado p. Thromb Haemost. 2022 Oct;122(10):1653-1661. doi: 10.1055/a-1816-8347. Epub 2022 Apr 5. Thromb Haemost. 2022. PMID: 35381615 Free PMC article.
25 results